Transgender women (TW) in Central America are the population most-affected by HIV/AIDS in the region. Antiretroviral therapy (ART) coverage and adherence among TW is assumed lower than national estimates because TW face additional barriers to care, greater stigma, and limited family and emotional support.
To inform a USAID-funded Combination Prevention Program in Central America, PASMO conducted a qualitative study to explore the barriers to adherence faced by people living with HIV, including TW. This study examines a subset of 10 life history interviews and two focus groups conducted with HIV-positive TW in Nicaragua, El Salvador, and Costa Rica.
The results were presented at the 10th International Conference on HIV Treatment and Prevention Adherence.